Treatment of uncomplicated urogenital gonorrhoea in women with a single oral dose of enoxacin

Tegelberg-Stassen, M. J. A. M.; Willigen, A. H. van der; Hoek, J. C. van der; Wagenvoort, J. H. T.; Vliet, Hans J. van der; Klingeren, B. Van; Joost, Theodoor van; Michel, M. F.; Stolz, E.

doi:10.1007/bf02075693

Cited by 12 publications

(15 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the MICs of enoxacin for penicillinaseproducing and non-penicillinase-producing N. gonorrhoeae strains were low (0.3 to 0.12 ,ug/ml) and agreed with those determined in previous studies (2,4,8) the cure rates in both groups of treated males were lower than expected from other studies with quinolones (4,12,13). Pre-and posttreatment isolates were available from six treatment failures in the 200-mg group and two failures in the 400-mg group.…”

Section: Resultssupporting

confidence: 87%

“…Our conclusion is that enoxacin is an effective drug in the treatment of uncomplicated male urethral gonorrhea, although the cure rate in this study was lower than that in previous studies of female patients and previous studies with other quinolones (13).…”

Section: Resultscontrasting

confidence: 87%

“…The cure rate found in this study, 90% in the 200-mg treatment group and 92% in the 400-mg treatment group, was lower than that in our previous study of enoxacin with identical doses in the treatment of uncomplicated female urogenital gonorrhea (13). The cure rates in the latter study were 98.7% in the 200-mg treatment group and 100% in the 400-mg treatment group.…”

Section: Resultscontrasting

confidence: 75%

See 2 more Smart Citations

Comparative double-blind study of 200- and 400-mg enoxacin given orally in the treatment of acute uncomplicated urethral gonorrhea in males

Willigen¹,

Hoek²,

Wagenvoort³

et al. 1987

Antimicrob Agents Chemother

View full text Add to dashboard Cite

In a double-blind randomized study, 155 male patients with uncomplicated urethral gonorrhea were given 200 mg (one capsule with 200 mg and one capsule with placebo; n = 77) or 400 mg (two capsules with 200 mg; n = 78) of enoxacin orally. The cure rates in the 200-and 400-mg treatment groups were 90 and 92%, respectively. The enoxacin MIC for the isolated Neisseria gonorrhoeae strains ranged from 0.015 to 0.12 ,ug/ml.Postgonococcal urethritis was diagnosed in 29 (42%) patients in the 200-mg treatment group and 19 (26%) patients in the 400-mg treatment group. Side effects (nausea, headache, and vomiting) occurred in 2 (3%) of the 77 patients in the 200-mg treatment group and in 3 (4%) of the 78 patients in the 400-mg treatment group.The increasing resistance of Neisseria gonorrhoeae to penicillins and tetracycline calls for new therapeutic agents. The 4-quinolone group has yielded some derivatives that are active against N. gonorrhoeae and can be given orally. Cure rates of up to 100% have been reported in previous studies with ciprofloxacin in the treatment of uncomplicated urogenital gonorrhea in males (12) and with enoxacin in the treatment of uncomplicated urogenital gonorrhea in females (4, 13). In vitro studies have shown that enoxacin, one of the new quinolone agents, is effective against N. gonorrhoeae with MICs of 0.03 to 0.25 ,ug/ml (8). Our double-blind randomized study involved clinical evaluation of the treatment of uncomplicated urethral gonorrhea in males with a single oral dose of either 200 or 400 mg of enoxacin. MATERIALS AND METHODSPatient population. All patients were men attending the outpatient clinic for sexually transmitted diseases at the University Hospital Rotterdam-Dijkzigt. Patients who were under 18, had disseminated gonococcal infections, had solitary rectal or pharyngeal gonococcal infections, had syphilis, liver, or kidney diseases, had allergies to quinolones, and were recently treated with enoxacin or on theophylline medication were excluded. This was a double-blind study. A randomization list ensured that patients received a single oral dose of either 400 mg of enoxacin in two 200-mg capsules or 200 mg of enoxacin in one 200-mg capsule and one placebo capsule. The capsules were taken with water under the supervision of a nurse. The patients were advised to abstain from sexual contacts throughout the follow-up period.All subjects gave oral informed consent before they were enrolled, and the study was approved by the committee for the protection of human subjects at the University Hospital Rotterdam-Dijkzigt.Venereological study. A standard history was taken, and all patients underwent the following tests before and after * Corresponding author.therapy. Gram stains were made of the discharge, and samples for Chlamydia trachomatis and N. gonorrhoeae cultures were taken from the urethra. N. gonorrhoeae culture samples were taken from the pharynx (and from the rectum in homosexual men), and the sediment of 10 to 15 ml of the first-voided urine was collected. Blood was drawn for Vener...

show abstract

Section: Resultssupporting

confidence: 87%

Section: Resultscontrasting

confidence: 87%

Section: Resultscontrasting

confidence: 75%

See 1 more Smart Citation

Comparative double-blind study of 200- and 400-mg enoxacin given orally in the treatment of acute uncomplicated urethral gonorrhea in males

Willigen¹,

Hoek²,

Wagenvoort³

et al. 1987

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Other open or comparative studies with single doses of norfloxacin (800 mg) (9, 44), ciprofloxacin (100 to 500 mg) (30,48,56), ofloxacin (200 to 600 mg) (3,14,33,42), enoxacin (200 to 600 mg) (4,38,50,55,60), or fleroxacin (400 mg) (8) confirmed the efficacy of fluoroquinolones in the treatment of uncomplicated gonorrhea. Treatment failures for gonococcal urethritis or cervicitis have been rare with these agents, except for patients treated with lower doses of enoxacin.…”

Section: Clinical Efficacy In Genital Tract Infectionsmentioning

confidence: 86%

“…Single doses of fluoroquinolones were effective in eradicating rectal (173 of 174 cases [99%]) and pharyngeal (37 of 41 cases [90%]) infections in both comparative (Table 1) and open (4,8,30,44,55,60) studies. In the comparative studies, rectal and pharyngeal infections were eradicated in 80 to 100% of patients given fluoroquinolones, in contrast to 16 to 33% of patients given ampicillin plus probenecid.…”

Section: Clinical Efficacy In Genital Tract Infectionsmentioning

confidence: 99%

Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects

Hooper

Wolfson

1989

Antimicrob Agents Chemother

View full text Add to dashboard Cite

INTRODUCTIONIn the first minireview (66) we considered the activity in vitro, pharmacokinetic properties, and efficacy of fluoroquinolones for the treatment of urinary tract infections and prostatitis. In this minireview we review the role of fluoroquinolones in the treatment of genital infections and summarize the adverse effects of these agents when used for the treatment of genitourinary tract infections.

show abstract

The Role of Fluoroquinolones in Sexually Transmitted Diseases

Tartaglione,

Hooton

1993

Pharmacotherapy

View full text Add to dashboard Cite

The management of sexually transmitted diseases (STDs) has reached a new level in the era of antibiotic resistance and human immunodeficiency virus infection. To date, no single antimicrobial is capable of eradicating the commonly encountered STD pathogens including Neisseria gonorrhoeae, Chlamydia trachomatis, and Treponema pallidum. Among the marketed fluoroquinolones, ciprofloxacin, ofloxacin, lomefloxacin, and enoxacin all provide excellent in vitro activity (MIC90 < 0.06 μg/ml) and excellent in vivo efficacy against N. gonorrhoeae, including multiply resistant isolates (penicillinase‐producing N. gonorrhoeae and chromosomally mediated resistant N. gonorrhoeae). Ofloxacin is the only fluoroquinolone approved by the Food and Drug Administration for chlamydial infection. All of the quinolones lack reliable in vitro activity against Ureaplasma urealyticum, a cause of nongonococcal urethritis. Although limited data suggest the usefulness of ciprofloxacin and ofloxacin in the treatment of pelvic inflammatory disease, these drugs cannot currently be recommended for single‐agent therapy. Haemophilus ducreyi infections, however, can be managed effectively with the fluoroquinolones. Although their role continues to evolve, this class of drugs cannot be used equally to treat all STDs, and notably, no quinolone to date inhibits T. pallidum.

show abstract

Treatment of uncomplicated urogenital gonorrhoea in women with a single oral dose of enoxacin

Cited by 12 publications

References 13 publications

Comparative double-blind study of 200- and 400-mg enoxacin given orally in the treatment of acute uncomplicated urethral gonorrhea in males

Comparative double-blind study of 200- and 400-mg enoxacin given orally in the treatment of acute uncomplicated urethral gonorrhea in males

Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects

The Role of Fluoroquinolones in Sexually Transmitted Diseases

Contact Info

Product

Resources

About